Skip to main content
. 2017 Jan 3;17(3):235–242. doi: 10.1007/s40256-016-0210-3

Table 2.

Serious adverse events in the treatment and control study groups during 6-month period

pl-VEGF165 (n = 150) Control (n = 60)
Number of amputations 6 (4%) 2 (3%)
AMI 1 1
ACVE 1 0
Mortality 3 2

ACVE acute cerebrovascular event, AMI acute myocardial infarction